Strategic partnerships Current funding and grants from DoD, NIH, CARB-X, and the Cystic Fibrosis Foundation, plus active licensing discussions, indicate strong interest from public and private partners. Leverage these signals to target potential pharma, biotech, and research collaborators for late-stage development and global commercialization deals.

Clinical momentum Phase 3 timing planned for 2025 for topical pravibismane and completed Phase 2a for local/surgical orthopedic infections demonstrates near-term near-market potential. Pursue co-development or licensing arrangements with companies seeking fast-to-market anti-infective and anti-biofilm solutions in wound care and orthopedic infection spaces.

Targeted indications A triad mechanism addressing anti-infective, antibiofilm, and anti-inflammatory needs positions pravibismane for unmet needs in diabetic foot infections, orthopedic infections, and nontuberculous mycobacterial lung diseases. Identify regional pharma with strength in infectious disease, orthopedics, and pulmonology for focused collaborations and term sheets.

Early-stage clinical positioning Inhaled and topical formulations ready for strategic partner-led Phase 1/3 pathways, suggesting opportunities with contract development and manufacturing organizations (CDMOs) and specialty pharma seeking portfolio diversification in rare and chronic disease therapies.

Funding-ready leverage Significant external funding history and high-profile endorsements imply readiness for co-investment rounds, milestone-driven deals, and government-aligned programs. Prioritize outreach to potential partners with appetite for FDA QIDP, Fast Track, and Orphan Drug-ready assets to accelerate regulatory timelines.